Survival in acute myeloid leukemia is associated with NKp44 splice variants

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32933-32945

  Shemesh, Avishai ^a   Brusilovsky, Michael ^a   Hadad, Uzi ^a   Teltsh, Omri ^a   Edri, Avishay ^a   Rubin, Eitan ^a   Campbell, Kerry S ^b   Rosental, Benyamin ^c   Porgador, Angel ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b FOX CHASE CANCER CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; Isoforms; Natural killer cells; NKp44; Splice variants

Indexed keywords

NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; ISOPROTEIN; NCR2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RNA SEQUENCE; UPREGULATION; ACUTE MYELOID LEUKEMIA; ADULT; CASE CONTROL STUDY; GENETICS; HELA CELL LINE; K-562 CELL LINE; METABOLISM; MORTALITY; SURVIVAL RATE;

ADULT; CASE-CONTROL STUDIES; HELA CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; PROTEIN ISOFORMS; SURVIVAL RATE;

EID: 84973531037     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8782     Document Type: Article

References (59)

1. Longo DL, Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New England Journal of Medicine. 2015; 373: 1136-1152.
2. Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood. 2014; 123: 1535-1543.
3. Liersch R, Müller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adultsbiological significance and clinical use. British journal of haematology. 2014; 165: 17-38.
4. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine. 2013; 368: 2059-2074.
5. Moffett-King A. Natural killer cells and pregnancy. Nature Reviews Immunology. 2002; 2: 656-663.
6. Wu J, Lanier LL. Natural killer cells and cancer. Advances in Cancer Research. 2003; 90: 127-156.
7. Hanna J, Mandelboim O. When killers become helpers. Trends in immunology. 2007; 28: 201-206.
8. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. Journal of immunology (Baltimore, Md.: 1950). 2007; 178: 4011-4016.
9. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nature immunology. 2008; 9: 503-510.
10. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008; 27: 5932-5943.
11. Deshmukh US, Bagavant H. When killers become helpers. Science translational medicine. 2013; 5: 195fs29.
12. Lion E, Willemen Y, Berneman Z, Van Tendeloo V, Smits E. Natural killer cell immune escape in acute myeloid leukemia. Leukemia. 2012; 26: 2019-2026.
13. Khaznadar Z, Henry G, Setterblad N, Agaugue S, Raffoux E, Boissel N, Dombret H, Toubert A, Dulphy N. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. European journal of immunology. 2014; 44: 3068-3080.
14. Khaznadar Z, Boissel N, Agaugue S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C, Raffoux E, Lachuer J, Sigaux F, et al. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. Journal of immunology (Baltimore, Md.: 1950). 2015; 195: 2580-2590.
15. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nature immunology. 2008; 9: 495-502.
16. Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin KM, Eckert C, Stanulla M, Schrappe M, et al. Central nervous system acute lymphoblastic leukemia: role of natural killer cells. Blood. 2015; 125: 3420-3431.
17. Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunology and cell biology. 2014; 92: 221-229.
18. Li Y, Mariuzza RA. Structural basis for recognition of cellular and viral ligands by NK cell receptors. Frontiers in immunology. 2014; 5.
19. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. The Journal of experimental medicine. 1998; 187: 2065-2072.
20. Allcock RJ, Barrow AD, Forbes S, Beck S, Trowsdale J. The human TREM gene cluster at 6p21. 1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. European journal of immunology. 2003; 33: 567-577.
21. De Maria A, Ugolotti E, Rutjens E, Mazza S, Radic L, Faravelli A, Koopman G, Di Marco E, Costa P, Ensoli B, Cafaro A, Mingari MC, Moretta L, et al. NKp44 expression, phylogenesis and function in non-human primate NK cells. International immunology. 2009; 21: 245-255.
22. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cellmediated cytolysis. Immunology today. 2000; 21: 228-234.
23. Brusilovsky M, Rosental B, Shemesh A, Appel MY, Porgador A. Human NK cell recognition of target cells in the prism of natural cytotoxicity receptors and their ligands. Journal of immunotoxicology. 2012; 9: 267-274.
24. Hershkovitz O, Jivov S, Bloushtain N, Zilka A, Landau G, Bar-Ilan A, Lichtenstein RG, Campbell KS, van Kuppevelt TH, Porgador A. Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry. 2007; 46: 7426-7436.
25. Ho JW, Hershkovitz O, Peiris M, Zilka A, Bar-Ilan A, Nal B, Chu K, Kudelko M, Kam YW, Achdout H, Mandelboim M, Altmeyer R, Mandelboim O, et al. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. Journal of virology. 2008; 82: 2028-2032.
26. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. European journal of immunology. 2001; 31: 2680-2689.
27. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, et al. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. Journal of immunology (Baltimore, Md.: 1950). 2009; 183: 2610-2621.
28. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood. 2013; 122: 2935-2942.
29. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, Yossef R, Rosenberg LA, Aharoni A, Cerwenka A, Campbell KS, Braiman A, Porgador A. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. Journal of immunology (Baltimore, Md.: 1950). 2011; 187: 5693-5702.
30. Rajagopalan S, Long EO. Found: a cellular activating ligand for NKp44. Blood. 2013; 122: 2921-2922.
31. Horton NC, Mathew SO, Mathew PA. Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PloS one. 2013; 8: e59552.
32. Chaturvedi C, Brand M. Gene Section. http:// AtlasGeneticsOncology.org. 2014: 38.
33. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. The Journal of experimental medicine. 2000; 192: 1059-1068.
34. Graveley BR. Alternative splicing: increasing diversity in the proteomic world. TRENDS in Genetics. 2001; 17: 100-107.
35. Sedy JR, Bjordahl RL, Bekiaris V, Macauley MG, Ware BC, Norris PS, Lurain NS, Benedict CA, Ware CF. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. Journal of immunology (Baltimore, Md.: 1950). 2013; 191: 828-836.
36. Shemesh A, Tirosh D, Sheiner E, Tirosh NB, Brusilovsky M, Segev R, Rosental B, Porgador A. First Trimester Pregnancy Loss and the Expression of alternatively spliced NKp30 isoforms in Maternal Blood and Placental Tissue. Name: Frontiers in Immunology. 2015; 6: 189.
37. Karimi MA, Aguilar OA, Zou B, Bachmann MH, Carlyle JR, Baldwin CL, Kambayashi T. A truncated human NKG2D splice isoform negatively regulates NKG2Dmediated function. Journal of immunology (Baltimore, Md.: 1950). 2014; 193: 2764-2771.
38. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nature medicine. 2011; 17: 700-707.
39. Rosental B, Hadad U, Brusilovsky M, Campbell KS, Porgador A. A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. Oncoimmunology. 2012; 1: 572-574.
40. Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood. 2005; 106: 2076-2082.
41. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE. Innate lymphoid cells-a proposal for uniform nomenclature. Nature Reviews Immunology. 2013; 13: 145-149.
42. Rham Cd, Ferrari-Lacraz S, Jendly S, Schneiter G, Dayer J, Villard J. The pro-inflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Research and Therapy. 2007; 9: R125.
43. Wang H, Hu H, Zhang Q, Yang Y, Li Y, Hu Y, Ruan X, Yang Y, Zhang Z, Shu C. Dynamic transcriptomes of human myeloid leukemia cells. Genomics. 2013; 102: 250-256.
44. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007; 109: 323-330.
45. Horton NC, Mathew PA. NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Frontiers in immunology. 2015; 6.
46. Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Frontiers in immunology. 2013; 4.
47. Wang S. PCNA: a silent housekeeper or a potential therapeutic target?. Trends in pharmacological sciences. 2014; 35: 178-186.
48. Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu W, Hendrickson R, Bargonetti J. Proteome-wide analysis of gain-of-function mutant p53 targets in breast cancer implicates PARP, PCNA and MCM4 as oncogenic drivers. Cancer research. 2015; 75: 1225-1225.
49. Siewiera J, Gouilly J, Hocine H, Cartron G, Levy C, Al-Daccak R, Jabrane-Ferrat N. Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes. Nature communications. 2015; 6.
50. Porgador A, Mandelboim O, Restifo NP, Strominger JL. Natural killer cell lines kill autologous beta2-microglobulindeficient melanoma cells: implications for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 13140-13145.
51. van Besien K. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology / the Education Program of the American Society of Hematology.American Society of Hematology. Education Program. 2013; 2013: 56-62.
52. Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology / the Education Program of the American Society of Hematology.American Society of Hematology.Education Program. 2013; 2013: 234-246.
53. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica. 2014; 2014.
54. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+high stage and effector functions. Journal of immunology (Baltimore, Md.: 1950). 2004; 172: 88-96.
55. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Journal of clinical oncology. 2010; 28: 955-959.
56. Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary Oncology. 2015; 19: A68.
57. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002; 30: 207-210.
58. Colonna M, Campbell KS. Natural killer cell protocols: cellular and molecular methods. Humana. 2000.
59. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B. Fiji: an open-source platform for biologicalimage analysis. Nature methods. 2012; 9: 676-682.